SCHEMBL4383435

SCHEMBL4383435

CC(C)CCC(C)NC(=O)c1csc(CNC(=O)COc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PREP P48147 1/20 0.38
FAP Q12884 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
LMNA P02545 2/20 0.38
THRB P10828 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
AHR P35869 1/20 0.38
MCHR1 Q99705 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.37
PDE2A O00408 4/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5670705 0.91 ALDH1A1 (0.40) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL4390778 0.90 ALDH1A1 (0.42) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL5668017 0.89 ALDH1A1 (0.44) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL4394123 0.87 ALDH1A1 (0.41) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL5667971 0.87 HDAC3 (0.41) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL4389979 0.85 PDE2A (0.49) ALDH1A1PDE2A
SCHEMBL5668567 0.85 PDE2A (0.47) ALDH1A1CYP1A2POLBCYP3A4CYP2C9
SCHEMBL4383956 0.84 PDE2A (0.46) ALDH1A1SMN1; SMN2KMT2APDE2A
SCHEMBL4387739 0.84 ALDH1A1 (0.42) ALDH1A1PREPFAPSCN10ASMN1; SMN2
SCHEMBL2172250 0.83 MEN1 (0.45) ALDH1A1SCN10ASMN1; SMN2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 ALDH1A1 1466/4885PREP 4562/4885FAP 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.